1
|
Barrett L, Waithman J, Fear V, Willis V, Kutub N, Jackson G, Wood F, Fear M. Investigating the link between burn injury and tumorigenesis. Ann Oncol 2019. [DOI: 10.1093/annonc/mdz268.041] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
2
|
Maleki Vareki S, Harding M, Waithman J, Zanker D, Shivji A, Rytelewski M, Mazzuca D, Yekta M, Chen W, Schell T, Haeryfar S. Differential regulation of simultaneous antitumor and alloreactive CD8(+) T-cell responses in the same host by rapamycin. Am J Transplant 2012; 12:233-9. [PMID: 22026814 PMCID: PMC3520512 DOI: 10.1111/j.1600-6143.2011.03811.x] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/25/2023]
Abstract
Rapamycin is an immunosuppressive agent routinely used in organ transplantation but also paradoxically exerts antiviral and antitumor activities. Pathogen-specific memory CD8(+) T-cell (T(CD8) ) responses were recently found to be augmented by rapamycin. However, whether rapamycin influences the magnitude and quality of anticancer T(CD8) responses is unknown. Importantly, how rapamycin may regulate simultaneous virus/tumor-specific and alloreactive T(CD8) in the same host remains unexplored. To answer these questions, we primed wild-type mice with allogeneic cells concomitantly expressing simian virus 40 large tumor antigen (T Ag), a viral oncoprotein with well-defined epitopes. Rapamycin selectively enhanced the cross-priming of T(CD8) specific for T Ag's most immunodominant epitope called site IV but not T(CD8) alloreactivity. Rapamycin-treated mice also had a high percentage of splenic CD127(high) KLRG1(low) T(CD8) and an increased frequency of site IV-specific T cells long after the peak of their primary response. When site IV was presented as a cytosolic minigene encoded by a recombinant vaccinia virus, rapamycin failed to boost the site IV-specific response. Therefore, the nature and presentation mode of antigen determine the susceptibility to the adjuvant effect of rapamycin. Our findings reveal the unexpected benefit of rapamycin treatment in recipients of allografts co-expressing tumor/viral Ags.
Collapse
Affiliation(s)
- S. Maleki Vareki
- Department of Microbiology and Immunology, University of Western Ontario, London, Canada
| | - M.J. Harding
- Department of Microbiology and Immunology, University of Western Ontario, London, Canada
| | - J. Waithman
- T Cell Laboratory, Ludwig Institute for Cancer Research, Melbourne-Austin Branch, Heidelberg, Australia
| | - D. Zanker
- T Cell Laboratory, Ludwig Institute for Cancer Research, Melbourne-Austin Branch, Heidelberg, Australia
| | - A.N. Shivji
- Department of Microbiology and Immunology, University of Western Ontario, London, Canada
| | - M. Rytelewski
- Department of Microbiology and Immunology, University of Western Ontario, London, Canada
| | - D.M. Mazzuca
- Department of Microbiology and Immunology, University of Western Ontario, London, Canada
| | - M.A. Yekta
- Department of Microbiology and Immunology, University of Western Ontario, London, Canada
| | - W. Chen
- T Cell Laboratory, Ludwig Institute for Cancer Research, Melbourne-Austin Branch, Heidelberg, Australia
| | - T.D. Schell
- Department of Microbiology and Immunology, Pennsylvania State University, Hershey, Pennsylvania, U.S.A
| | - S.M.M. Haeryfar
- Department of Microbiology and Immunology, University of Western Ontario, London, Canada,Centre for Human Immunology, University of Western Ontario, London, Ontario, Canada,Corresponding author: S.M. Mansour Haeryfar, Department of Microbiology and Immunology, University of Western Ontario, 1151 Richmond Street, London, Ontario N6A 5C1, Canada. Phone: (519) 850-2488; Fax: (519) 661-3499;
| |
Collapse
|
3
|
Henri S, Vremec D, Kamath A, Waithman J, Williams S, Benoist C, Burnham K, Saeland S, Handman E, Shortman K. The dendritic cell populations of mouse lymph nodes. J Immunol 2001; 167:741-8. [PMID: 11441078 DOI: 10.4049/jimmunol.167.2.741] [Citation(s) in RCA: 330] [Impact Index Per Article: 14.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
Abstract
The dendritic cells (DC) of mouse lymph nodes (LN) were isolated, analyzed for surface markers, and compared with those of spleen. Low to moderate staining of LN DC for CD4 and low staining for CD8 was shown to be attributable to pickup of these markers from T cells. Excluding this artifact, five LN DC subsets could be delineated. They included the three populations found in spleen (CD4(+)8(-)DEC-205(-), CD4(-)8(-)DEC-205(-), CD4(-)8(+)DEC-205(+)), although the CD4-expressing DC were of low incidence. LN DC included two additional populations, characterized by relatively low expression of CD8 but moderate or high expression of DEC-205. Both appeared among the DC migrating out of skin into LN, but only one was restricted to skin-draining LN and was identified as the mature form of epidermal Langerhans cells (LC). The putative LC-derived DC displayed the following properties: large size; high levels of class II MHC, which persisted to some extent even in CIITA null mice; expression of very high levels of DEC-205 and of CD40; expression of many myeloid surface markers; and no expression of CD4 and only low to moderate expression of CD8. The putative LC-derived DC among skin emigrants and in LN also showed strong intracellular staining of langerin.
Collapse
Affiliation(s)
- S Henri
- Walter and Eliza Hall Institute of Medical Research, P.O. Royal Melbourne Hospital, Victoria 3050, Australia.
| | | | | | | | | | | | | | | | | | | |
Collapse
|